Kim joined Alliance Advisors Investor Relations in 2023 through the acquisition of LHA, which she joined in 1998.

Over the last two decades at LHA, she rose through the ranks to Senior Vice President and Principal. Drawing from more than 15 years of Wall Street experience, including several years as a sell-side securities analyst, she provides her clients with first-hand perspective on how the Street evaluates companies, how analysts build their models and, most importantly, how management’s communications affect credibility and valuation.

Clients have utilized Kim’s experience as a corporate relations manager at the American Stock Exchange to navigate through listing-related issues. During her tenure at LHA, Kim has guided many clients through introductions and investment banking relationships in support of IPOs, follow-on offerings and PIPEs that led to approximately half a billion dollars in funds raised.

She is a full-service IR practitioner, and her capabilities run the gamut from traditional tactics – including the preparation of written materials, such as conference call scripts, presentations, press releases and corporate Fact sheets, to consulting on corporate positioning. As a long-time veteran of the firm’s healthcare practice, Kim has knowledge of various FDA regulatory pathways, including Pre-market Approvals (PMAs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and 510(k) Applications. She was previously director of investor relations for a microcap company during a change in management and business focus from a biotechnology company to a drug delivery/medical device company.

Kim received a BA in English from the State University of New York at Albany and an MBA in International Business and Finance from Pace University.